Drug General Information |
Drug ID |
D01ARE
|
Former ID |
DNC004832
|
Drug Name |
Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C10H10N2S
|
Canonical SMILES |
CNC1=CC=C(S1)C2=CN=CC=C2
|
InChI |
1S/C10H10N2S/c1-11-10-5-4-9(13-10)8-3-2-6-12-7-8/h2-7,11H,1H3
|
InChIKey |
OUEHWWLIEPNPDR-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Cytochrome P450 2D6 |
Target Info |
Inhibitor |
[1]
|
Cytochrome P450 3A4 |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Metabolism of xenobiotics by cytochrome P450
|
Drug metabolism - cytochrome P450
|
Serotonergic synapsehsa00140:Steroid hormone biosynthesis
|
Linoleic acid metabolism
|
Retinol metabolism
|
Drug metabolism - other enzymes
|
Metabolic pathways
|
Bile secretion
|
Chemical carcinogenesis
|
PathWhiz Pathway
|
Caffeine Metabolism
|
Retinol Metabolism
|
Reactome
|
XenobioticsR-HSA-211981:Xenobiotics
|
Aflatoxin activation and detoxification
|
WikiPathways
|
Metapathway biotransformation
|
Tamoxifen metabolism
|
Oxidation by Cytochrome P450
|
Vitamin D Receptor Pathway
|
Aripiprazole Metabolic Pathway
|
Fatty Acid Omega Oxidation
|
Codeine and Morphine MetabolismWP702:Metapathway biotransformation
|
Aflatoxin B1 metabolism
|
Estrogen metabolism
|
Benzo(a)pyrene metabolism
|
Tryptophan metabolism
|
Nuclear Receptors in Lipid Metabolism and Toxicity
|
Nuclear Receptors Meta-Pathway
|
Farnesoid X Receptor Pathway
|
Felbamate Metabolism
|
Lidocaine metabolism
|
Nifedipine Activity
|
Colchicine Metabolic Pathway
|
Irinotecan Pathway
|
Drug Induction of Bile Acid Pathway
|
Codeine and Morphine Metabolism
|
References |
REF 1 | J Med Chem. 2005 Jan 13;48(1):224-39.5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. |